Nebenwirkungen · Leqvio
Leqvio 284 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 5
HOS-146429 · Präparat HOS-099518
In the phase III clinical studies, there were more frequent elevations of serum hepatic transaminases between >1x the upper limit of normal (ULN) and ≤3x ULN in patients on inclisiran (ALT: 19.7% and AST: 17.2%) than in patients on placebo (ALT: 13.6% and AST: 11.1%). These elevations did not progress to exceed the clinically relevant threshold of 3x ULN, were asymptomatic and were not associated with adverse reactions or other evidence of liver dysfunction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:00:00Z · SHA-256 8ca71d1fd7bc5e2a47da2e9fbf75972c9eacf2c37333f4bb35c0e09c5b7316ef · Passage b8b1a5e4d8c75c3f2f1be8e96e97e7b9b98c8ba287c58ffe8325efc2c0493c59 · Zeichen 3423–3885 im Abschnitt